Ostoros G, Pretz A, Fillinger J, Soltesz I, Dome B
Department of Pulmonology, National Koranyi Institute of Pulmonology, Budapest, Hungary.
Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:391-3. doi: 10.1111/j.1525-1438.2006.00222.x.
Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer. Four weeks after the end of the chemotherapy she developed interstitial pneumonitis and irreversible lung fibrosis. Despite treatment with corticosteroids, she had rapid deterioration and died of respiratory failure. Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids. While reviewing the literature, we found few less severe pulmonary injuries after intravenous use of paclitaxel, but none of these cases had a fatal outcome. Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.
由紫杉醇毒性引起的致命性肺纤维化此前未见报道。在本报告中,我们描述了一名62岁女性的病例,她接受了六个周期的紫杉醇和卡铂联合化疗,用于晚期卵巢癌的治疗。化疗结束四周后,她出现了间质性肺炎和不可逆的肺纤维化。尽管接受了皮质类固醇治疗,她的病情仍迅速恶化,最终死于呼吸衰竭。肺纤维化是紫杉醇治疗的一种并发症,即便使用皮质类固醇治疗也可能发生。在查阅文献时,我们发现静脉使用紫杉醇后发生的肺部损伤较少有严重程度较低的情况,但这些病例均无致命结局。医生应牢记,诸如紫杉醇之类的紫杉烷类药物有可能导致肺炎和肺纤维化。